Head to Head Comparison: Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) versus Boston Scientific (NYSE:BSX)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Valuation and Earnings

This table compares Health Sciences Acquisitions Co. 2 and Boston Scientific”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Boston Scientific	$16.75 billion	7.93	$1.85 billion	$1.25	71.82

Boston Scientific has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Insider and Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 0.5% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Health Sciences Acquisitions Co. 2 and Boston Scientific, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00
Boston Scientific	0	1	21	1	3.00

Boston Scientific has a consensus price target of $108.91, suggesting a potential upside of 21.32%. Given Boston Scientific’s stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Health Sciences Acquisitions Co. 2.

Volatility & Risk

Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Boston Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Boston Scientific	11.07%	17.80%	9.85%

Summary

Boston Scientific beats Health Sciences Acquisitions Co. 2 on 10 of the 12 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.